Erik A.C. Wiemer

10.4k citations

158 papers · 8.2k indexed · h-index 50

Cancer Research top 0.5%
- MicroRNA in disease regulation 19
- Cancer-related molecular mechanisms research 12
Oncology top 1%
- Drug Transport and Resistance Mechanisms 24
- Cancer Treatment and Pharmacology 15
Molecular Biology top 1%
- Peroxisome Proliferator-Activated Receptors 13
- DNA Repair Mechanisms 9
Hematology top 1%
Gastroenterology top 2%
- Gastrointestinal Tumor Research and Treatment 12
Pulmonary and Respiratory Medicine
- Sarcoma Diagnosis and Treatment 10

Co-authors: Ron H.J. Mathijssen Jaap Verweij Herman Burger Pieter Sonneveld Antonius W.M. Boersma Stefan Sleijfer Marieke H. Mossink Kees Nooter
Cited by: Cancer Research Oncology Molecular Biology
Journals: Science (1 paper)Proceedings of the National Academy of Sciences (1 paper)Journal of Biological Chemistry (3 papers)
Partner nations: Netherlands United States Belgium

In The Last Decade

Erik A.C. Wiemer

156 papers receiving 8.1k citations

Peers

Countries citing papers authored by Erik A.C. Wiemer

Since Specialization

Citations

This map shows the geographic impact of Erik A.C. Wiemer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik A.C. Wiemer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik A.C. Wiemer more than expected).

Fields of papers citing papers by Erik A.C. Wiemer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik A.C. Wiemer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik A.C. Wiemer. The network helps show where Erik A.C. Wiemer may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Erik A.C. Wiemer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Erik A.C. Wiemer Line = papers co-authored together Erik A.C. Wiemer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	PL02.2.A TRAMETINIB IN NEUROFIBROMATOSIS TYPE 1 RELATED SYMPTOMATIC PLEXIFORM NEUROFIBROMAS: ONE-YEAR FOLLOW-UP OF THE TRAIN STUDY Neuro-Oncology ·D. Christine Noordhoek,Sarah A. van Dijk,Pim J. French,Erik A.C. Wiemer,David F. Hanff,Olivier C. Manintveld,Walter Taal	2024	0
2	Major vault protein (MVP) suppresses aging- and estrogen deficiency-related bone loss through Fas-mediated apoptosis in osteoclasts Cell Death and Disease ·Ruobing Wang,Yan Yang,Zhong‐Yin Zhang,Na Zhao,Erik A.C. Wiemer,Jingjing Ben,Junqing Ma,Lichan Yuan	2023	10
3	miR-196b-5p and miR-107 Expression Differentiates Ocular Sebaceous Carcinoma from Squamous Cell Carcinoma of the Conjunctiva International Journal of Molecular Sciences ·Ronald O. B. de Keizer,Anne L. M. Vriends,Gijsbert J. Hötte,Dion Paridaens,Erik A.C. Wiemer,Robert M. Verdijk	2022	4
4	Cell-type-specific role of CHK2 in mediating DNA damage-induced G2 cell cycle arrest Oncogenesis ·Marijn T. M. van Jaarsveld,Difan Deng,Diana Ordoñez‐Rueda,Malte Paulsen,Erik A.C. Wiemer,Zhike Zi	2020	30
5	Major vault protein suppresses obesity and atherosclerosis through inhibiting IKK–NF-κB signaling mediated inflammation Nature Communications ·Jingjing Ben,Bin Jiang,Dongdong Wang,Qingling Liu,Yongjing Zhang,Yu Qi,Tong Xing,Lili Chen,Xianzhong Liu,Yan Zhang,Xudong Zhu,Xiaoyu Li,Hanwen Zhang,Hui Bai,Qing Yang,Junqing Ma,Erik A.C. Wiemer,Yong Xu,Qi Chen	2019	101
6	Aberrant MicroRNA Expression and Its Implications for Uveal Melanoma Metastasis Cancers ·Kyra N. Smit,Jiang Chang,Kasper Derks,Jolanda Vaarwater,Tom Brands,Robert M. Verdijk,Erik A.C. Wiemer,Hanneke W. Mensink,Joris Pothof,Annelies de Klein,Emine Kılıç	2019	31
7	Tissue-Specific Chk1 Activation Determines Apoptosis by Regulating the Balance of p53 and p21 iScience ·Marijn T. M. van Jaarsveld,Difan Deng,Erik A.C. Wiemer,Zhike Zi	2019	9
8	Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations European Journal of Surgical Oncology ·Milea J. M. Timbergen,M. Janssen,Cornelis Verhoef,Dirk J. Grünhagen,Frédéric Chibon,Marcel Smid,Stefan Sleijfer,Erik A.C. Wiemer	2018	4
9	MiR-193b promotes autophagy and non-apoptotic cell death in oesophageal cancer cells BMC Cancer ·Michelle J. Nyhan,Tracey R. O’Donovan,Antonius W.M. Boersma,Erik A.C. Wiemer,Sharon L. McKenna	2016	49
10	Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors Clinical Cancer Research ·Diane A.J. van der Biessen,Herman Burger,Peter de Bruijn,C. B. H. W. Lamers,Nicole C. Naus,Hannes Loferer,Erik A.C. Wiemer,Ron H.J. Mathijssen,Maja J.A. de Jonge	2014	27
11	Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors Clinical Cancer Research ·Ferry A.L.M. Eskens,Francisco Javier Ramos,Herman Burger,James P. O’Brien,Adelaida Piera,Maja J.A. de Jonge,Yoshiharu Mizui,Erik A.C. Wiemer,Maria Josepa Carreras,José Baselga,Josep Tabernero	2013	195
12	CYP3A422* Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity Clinical Cancer Research ·Anne‐Joy M. de Graan,Laure Elens,Jason A. Sprowl,Alex Sparreboom,Lena E. Friberg,Bronno van der Holt,Pleun J. de Raaf,Peter de Bruijn,Frederike K. Engels,Ferry A.L.M. Eskens,Erik A.C. Wiemer,Jaap Verweij,Ron H.J. Mathijssen,Ron H. N. van Schaik	2013	91
13	Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy Clinical Cancer Research ·Anne‐Joy M. de Graan,Walter J. Loos,Lena E. Friberg,Sharyn D. Baker,Jessica M. van der Bol,Leni van Doorn,Erik A.C. Wiemer,Bronno van der Holt,Jaap Verweij,Ron H.J. Mathijssen	2012	29
14	A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients Clinical Cancer Research ·Karel Eechoute,Martin N. Fransson,An K. Reyners,Floris A. de Jong,Alex Sparreboom,Winette T.A. van der Graaf,Lena E. Friberg,Gaia Schiavon,Erik A.C. Wiemer,Jaap Verweij,Walter J. Loos,Ron H.J. Mathijssen,Ugo De Giorgi	2012	87
15	Correction: Recruitment of the Major Vault Protein by InlK: A Listeria monocytogenes Strategy to Avoid Autophagy PLoS Pathogens ·Laurent Dortet,Serge Mostowy,Ascel Samba‐Louaka,Edith Gouin,Marie‐Anne Nahori,Erik A.C. Wiemer,Olivier Dussurget,Pascale Cossart	2011	23
16	A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan Clinical Cancer Research ·Jessica M. van der Bol,Ron H.J. Mathijssen,Geert-Jan Creemers,André Planting,Walter J. Loos,Erik A.C. Wiemer,Lena E. Friberg,Jaap Verweij,Alex Sparreboom,Floris A. de Jong	2010	50
17	Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. PubMed ·Marieke H. Mossink,Arend van Zon,Erna Fränzel‐Luiten,Martijn Schoester,Valerie A. Kickhoefer,George L. Scheffer,Rik J. Scheper,Pieter Sonneveld,Erik A.C. Wiemer	2002	75
18	Up-Regulation of Drug Resistance-Related Vaults During Dendritic Cell Development The Journal of Immunology ·Anouk B. Schroeijers,Anneke W. Reurs,George L. Scheffer,Anita G.M. Stam,Mariska C. de Jong,Thomas Rustemeyer,Erik A.C. Wiemer,Tanja D. de Gruijl,Rik J. Scheper	2002	49
19	The Mr 193,000 vault protein is up-regulated in multidrug-resistant cancer cell lines. PubMed ·Schroeijers Ab,Siva Ac,Scheffer Gl,de Jong,Bolick Sc,Dukers Df,Slootstra Jw,Meloen Rh,Erik A.C. Wiemer,Kickhoefer Va,Leonard H. Rome,Scheper Rj	2000	43
20	Phylogenetic Analysis Based On Glycolytic-enzymes DIAL (Catholic University of Leuven) ·Paul A.M. Michels,Fred R. Opperdoes,Véronique Hannaert,Erik A.C. Wiemer,Sylvie Allert,Nathalie Chevalier	1992	8

About Erik A.C. Wiemer

Erik A.C. Wiemer is a scholar working on Gastroenterology, Cancer Research and Oncology, having authored 158 papers that have together received 8.2k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (24 papers), MicroRNA in disease regulation (19 papers), Cancer Treatment and Pharmacology (15 papers), Peroxisome Proliferator-Activated Receptors (13 papers), Gastrointestinal Tumor Research and Treatment (12 papers), Cancer-related molecular mechanisms research (12 papers), Sarcoma Diagnosis and Treatment (10 papers) and DNA Repair Mechanisms (9 papers). The work is most often cited by research in Cancer Research (2.1k citations), Oncology (2.4k citations) and Molecular Biology (4.8k citations). Erik A.C. Wiemer has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Ron H.J. Mathijssen, Jaap Verweij, Herman Burger, Pieter Sonneveld, Antonius W.M. Boersma, Stefan Sleijfer, Marieke H. Mossink, Kees Nooter, Walter J. Loos and Rik J. Scheper. Their work appears in journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact